RAJESHREE DIMKPA: Open Payments
NPI 1194793240 · SALISBURY, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$892 in 47 payments from 11 companies in 2025. Trend: 2023 $1,481 · 2024 $624 · 2025 $892
Food & beverage: $892
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $184 |
| Neurocrine BioSciences, Inc. | 7 | $158 |
| E.R. Squibb & Sons, L.L.C. | 6 | $90 |
| Teva Pharmaceuticals USA, Inc. | 4 | $81 |
| Alkermes, Inc. | 3 | $74 |
| ABBVIE INC. | 3 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $55 |
| Supernus Pharmaceuticals, Inc. | 3 | $50 |
| Almatica Pharma LLC | 3 | $50 |
| Braeburn Inc. | 3 | $49 |
Products named: INGREZZA, ABILIFY ASIMTUFII, COBENFY, REXULTI, ARISTADA, VRAYLAR, CAPLYTA, Qelbree.
Industry payments across NC — which companies pay providers there.
